☰

Daniel A. Rauch, Ph.D. - Publications

Affiliations: 
2001 University of Iowa, Iowa City, IA 
Area:
Microbiology Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Rauch DA, Olson SL, Harding JC, Sundaramoorthi H, Kim Y, Zhou T, MacLeod AR, Challen G, Ratner L. Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma. Retrovirology. 17: 27. PMID 32859220 DOI: 10.1186/S12977-020-00535-Z  0.318
2020 Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Mey U, Blum S, Rauch D, O'Meara Stern A, Cantoni N, et al. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. Blood Advances. 4: 3699-3707. PMID 32777066 DOI: 10.1182/Bloodadvances.2020002160  0.337
2019 Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang X, Ren X, Olson S, Cheng X, Miljkovic MD, Sundaramoorthi H, Joseph A, Skidmore ZL, Griffith O, et al. . Blood. PMID 31467059 DOI: 10.1182/Blood.2019002038  0.312
2019 Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood. PMID 31101627 DOI: 10.1182/Blood-2018-10-879643  0.333
2018 Cherian MA, Olson S, Sundaramoorthi H, Cates K, Cheng X, Harding J, Martens A, Challen GA, Tyagi M, Ratner L, Rauch D. An activating mutation of interferon regulatory factor 4 (IRF4) in adult T cell leukemia. The Journal of Biological Chemistry. PMID 29540473 DOI: 10.1074/Jbc.Ra117.000164  0.322
2018 Benz RA, Arn K, Andres M, Pabst T, Novak U, Hitz F, Zenhäusern R, Chalandon Y, Mey U, Blum S, Rauch D, Nettekoven W, Cantoni N, Bargetzi M, O'Meara A, et al. Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research) Blood. 132: 2875-2875. DOI: 10.1182/Blood-2018-99-114301  0.339
2017 Rothschild S, Amrein M, Riether C, Gautschi O, Schuster N, Li Q, Savic S, Schneider M, Biaggi C, Bubendorf L, Brutsche M, Zippelius A, Zander T, Betticher D, Früh M, ... ... Rauch D, et al. MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09) Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.592  0.318
2016 Peters S, Stahel RA, Dafni U, Aix SP, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Noguera JG, Curioni-Fontecedro A, Rauch D, et al. Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28017787 DOI: 10.1016/J.Jtho.2016.12.017  0.353
2016 Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, et al. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical Lung Cancer. PMID 27993482 DOI: 10.1016/J.Cllc.2016.11.007  0.329
2016 Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, et al. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. Bmc Cancer. 16: 780. PMID 27724870 DOI: 10.1186/S12885-016-2823-Y  0.326
2016 Ratner L, Rauch D, Abel H, Caruso B, Noy A, Barta SK, Parekh S, Ramos JC, Ambinder R, Phillips A, Harding J, Baydoun HH, Cheng X, Jacobson S. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood Cancer Journal. 6: e408. PMID 27015285 DOI: 10.1038/Bcj.2016.21  0.305
2016 Kimby E, Rondeau S, Vanazzi A, Ostenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson A, Brown PdN, Hagberg H, Ferreri AJM, Lohri A, Novak U, et al. Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10 Blood. 128: 1099-1099. DOI: 10.1182/Blood.V128.22.1099.1099  0.324
2015 Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, et al. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26712227 DOI: 10.1200/Jco.2015.61.3968  0.328
2015 Mueller BU, Keller S, Seipel K, Mansouri Taleghani B, Rauch D, Betticher D, Egger T, Pabst T. Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leukemia & Lymphoma. 1-8. PMID 26294015 DOI: 10.3109/10428194.2015.1079315  0.31
2015 Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, ... ... Rauch D, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet (London, England). 386: 1049-56. PMID 26275735 DOI: 10.1016/S0140-6736(15)60294-X  0.338
2015 Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, et al. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical Lung Cancer. PMID 25843489 DOI: 10.1016/J.Cllc.2015.02.007  0.343
2015 Helbling D, Bodoky G, Gautschi O, Hayoz S, Bosman F, Madlung A, Gloor B, Burkhard R, Rauch D, Winterhalder RC, Saletti P, Widmer L, Borner MM, Baertschi D, Yan P, et al. Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07). Journal of Clinical Oncology. 33: 762-762. DOI: 10.1200/Jco.2015.33.3_Suppl.762  0.324
2015 Ratner L, Ramos J, Noy A, Barta S, Parikh S, Phillips A, Ambinder R, Rauch D, Harding J, Baydoun H, Cheng X, Caruso B, Jacobson S. Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma Retrovirology. 12. DOI: 10.1186/1742-4690-12-S1-P21  0.34
2015 Cathomas R, Crabb S, Kenner H, Mark M, Rothermundt C, Elliott T, Winterhalder R, Burg PV, Vilei SB, Hayoz S, Rauch D, Roggero E, Stenner F, Berthold D, Erdmann A, et al. 2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11) European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(15)30045-9  0.305
2014 Rochlitz C, Moos Rv, Bigler M, Zaman K, Anchisi S, Küng M, Na KJ, Baertschi D, Borner MM, Rordorf T, Rauch D, Mueller A, Ruhstaller T, Vetter M, Bernhard J, et al. SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial. Journal of Clinical Oncology. 32: 518-518. DOI: 10.1200/Jco.2014.32.15_Suppl.518  0.333
2014 Kimby E, Martinelli G, Ostenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson A, Brown PdN, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, et al. Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10 Blood. 124: 799-799. DOI: 10.1182/Blood.V124.21.799.799  0.303
2013 Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, Burkhard R, Winterhalder R, Madlung A, Rauch D, Saletti P, Widmer L, Borner M, Baertschi D, Yan P, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 718-25. PMID 23139259 DOI: 10.1093/Annonc/Mds519  0.305
2013 Früh M, Cathomas R, Siano M, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clinical Lung Cancer. 14: 34-9. PMID 22633220 DOI: 10.1016/J.Cllc.2012.04.001  0.349
2013 Pless M, Stupp R, Ris H, Stahel RA, Weder W, Thierstein S, Xyrafas A, Frueh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, ... Rauch D, et al. Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). Journal of Clinical Oncology. 31: 7503-7503. DOI: 10.1200/Jco.2013.31.15_Suppl.7503  0.32
2012 Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer (Amsterdam, Netherlands). 78: 239-44. PMID 23009726 DOI: 10.1016/J.Lungcan.2012.08.017  0.322
2011 Rauch DA, Ratner L. Targeting HTLV-1 activation of NFκB in mouse models and ATLL patients. Viruses. 3: 886-900. PMID 21994759 DOI: 10.3390/V3060886  0.334
2008 D'Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, Bihl M, Mayer M, Ribi K, Lerch S, Bubendorf L, Betticher DC. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 739-45. PMID 18096565 DOI: 10.1093/Annonc/Mdm564  0.355
2007 Hess D, Koberle D, Thurlimann B, Pagani O, Schonenberger A, Mattmann S, Rochlitz C, Rauch D, Schuller JC, Ballabeni P, Ribi K. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Oncology. 73: 228-37. PMID 18424887 DOI: 10.1159/000127414  0.323
2006 Salzberg M, Borner M, Bauer JA, Morant R, Rauch D, Rochlitz C. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. European Journal of Cancer (Oxford, England : 1990). 42: 2660-1. PMID 16934972 DOI: 10.1016/J.Ejca.2006.06.009  0.355
2006 D'Addario G, Strasser F, Ribi K, Rauch D, Stupp R, Pless M, Stahel RA, Rufibach K, Lerch S, Betticher D. Quality of life (QoL) in SAKK 19/03: A multicenter phase II study of first-line gefitinib followed by chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Swiss Group for Clinical Cancer Research (SAKK) Journal of Clinical Oncology. 24: 18559-18559. DOI: 10.1200/Jco.2006.24.18_Suppl.18559  0.325
2005 Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: 282-8. PMID 15668285 DOI: 10.1093/Annonc/Mdi047  0.316
2005 D'Addario G, Rauch D, Stupp R, Stahel R, Pless M, Mach N, Rufibach K, Petersen J, Betticher DC. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small cell lung cancer (NSCLC): Preliminary results. A study of the Swiss Group for Clinical Cancer Research (SAKK) Journal of Clinical Oncology. 23: 7128-7128. DOI: 10.1200/Jco.2005.23.16_Suppl.7128  0.326
2004 Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Roth A. The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 8120. PMID 28015335 DOI: 10.1200/Jco.2004.22.14_Suppl.8120  0.313
2004 Uhlmann C, Ballabeni P, Rijken N, Brauchli P, Mingrone W, Rauch D, Pestalozzi BC, Rochlitz C, Aebi S. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial. Oncology. 67: 117-122. PMID 15539915 DOI: 10.1159/000080997  0.301
2001 Huber MT, Wisner TW, Hegde NR, Goldsmith KA, Rauch DA, Roller RJ, Krummenacher C, Eisenberg RJ, Cohen GH, Johnson DC. Herpes simplex virus with highly reduced gD levels can efficiently enter and spread between human keratinocytes. Journal of Virology. 75: 10309-18. PMID 11581399 DOI: 10.1128/Jvi.75.21.10309-10318.2001  0.619
2000 Rauch DA, Rodriguez N, Roller RJ. Mutations in herpes simplex virus glycoprotein D distinguish entry of free virus from cell-cell spread. Journal of Virology. 74: 11437-46. PMID 11090139 DOI: 10.1128/Jvi.74.24.11437-11446.2000  0.624
1998 Roller RJ, Rauch D. Herpesvirus entry mediator HVEM mediates cell-cell spread in BHK(TK-) cell clones Journal of Virology. 72: 1411-1417. PMID 9445042 DOI: 10.1128/Jvi.72.2.1411-1417.1998  0.626
Show low-probability matches.